With 0.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.43 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.515 whereas the lowest price it dropped to was $3.435. The 52-week range on AVIR shows that it touched its highest point at $4.14 and its lowest point at $2.45 during that stretch. It currently has a 1-year price target of $6.00. Beta for the stock currently stands at 0.25.
Price Performance and Earnings:
Three-month performance surged to 21.60% while six-month performance rose 7.72%. The stock gained 4.18% in the past year, while it has lost -2.24% so far this year. A look at the trailing 12-month EPS for AVIR yields -1.65 with Next year EPS estimates of -1.71. For the next quarter, that number is -0.41. This implies an EPS growth rate of -8.50% for this year and 21.20% for next year. EPS is expected to grow by 12.39% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -63.72%.
Float and Shares Shorts:
At present, 85.58 million AVIR shares are outstanding with a float of 69.36 million shares on hand for trading. On 2025-06-30, short shares totaled 3.81 million, which was 444.99997 higher than short shares on 1748563200. In addition to Dr. Jean-Pierre Sommadossi Ph.D. as the firm’s Founder, Chairman, CEO & President, Ms. Andrea J. Corcoran J.D. serves as its CFO, Executive VP of Legal & Secretary.
Institutional Ownership:
Through their ownership of 0.66863 of AVIR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, AVIR reported revenue of $0.0 and operating income of -$39041000.0. The EBITDA in the recently reported quarter was -$38937000.0 and diluted EPS was -$0.4.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With AVIR analysts setting a high price target of 9.0 and a low target of 6.0, the average target price over the next 12 months is 7.5. Based on these targets, AVIR could surge 157.88% to reach the target high and rise by 71.92% to reach the target low. Reaching the average price target will result in a growth of 114.9% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.74135 being high and -$1.89394 being low. For AVIR, this leads to a yearly average estimate of -$1.80418. Based on analyst estimates, the high estimate for the next quarter is -$0.4 and the low estimate is -$1.5. The average estimate for the next quarter is thus -$0.78.
